Abstract: A human neutralizing monoclonal antibody is directed against the VP1 protein of JC virus. The JC virus is responsible for progressive multifocal leukoencephalopathy (PML). The antibody is used in a therapeutic or prophylactic treatment of a JCV infection or of a disease associated with a JCV infection, such as progressive multifocal leukoencephalopathy (PML). The antibody is also used in the diagnosis of JCV infections or of diseases associated with JCV infections.

Abstract: The use of monoclonal antibodies Fab28 and Fab49 for the prophylactic or therapeutic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections is described, the which virus is responsible for the influenza syndrome commonly known as “swine flu”. Moreover, the use of the above-mentioned antibodies for selecting potential vaccines for active immunization against S-OIV is described.

Abstract: A process is provided for the preparation of antibodies or fragments thereof using a prokaryotic host cell containing DNA sequences encoding for said antibodies of fragments thereof, wherein said DNA sequence is derived from a coronary plaque sample. Compositions containing said antibodies are also provided. Ligands to said antibodies and compositions containing said ligands are also described.

Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.

Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.